"Methods And Systems For Diagnosis, Classification, And Treatment Of Small Cell Lung Cancer And Other High-Grade Neuroendocrine Carcinomas" in Patent Application Approval Process (USPTO 20240150848).
In: Immunotherapy Weekly, 2024-05-27, S. 1086-1086
serialPeriodical
Zugriff:
A patent application from the University of Texas System has been released, outlining methods and systems for diagnosing, classifying, and treating small cell lung cancer (SCLC) and other high-grade neuroendocrine carcinomas (HGNEC). Currently, there are no established biomarkers for classifying these diseases or predicting response to different treatments, and there are no blood-based biomarkers for diagnosing SCLC or HGNEC. The patent application proposes using analysis of methylation sites in tumor DNA to identify different subtypes of SCLC and suggests treatment methods using specific inhibitors and therapies. These methods aim to address the need for biomarkers and more effective treatments for SCLC and HGNEC. [Extracted from the article]
Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
"Methods And Systems For Diagnosis, Classification, And Treatment Of Small Cell Lung Cancer And Other High-Grade Neuroendocrine Carcinomas" in Patent Application Approval Process (USPTO 20240150848).
|
---|---|
Zeitschrift: | Immunotherapy Weekly, 2024-05-27, S. 1086-1086 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1090-8625 (print) |
Schlagwort: |
|
Sonstiges: |
|